《生命科学》 2023, 35(7): 876-882

STAT3在甲状腺癌中的研究进展

吴沙沙¹ , 刘　枫^2,*

¹四川大学华西医院人类疾病和免疫治疗研究室，成都 610041 ²四川大学华西医院甲状腺外科，成都 610041

摘　要：

甲状腺癌是常见的内分泌恶性肿瘤，其全球发病率持续上升。大部分甲状腺癌治疗效果良好，但一些手术难以切除且碘131 难治的甲状腺癌预后较差。对于预后较差的甲状腺癌目前可采用靶向治疗。甲状腺癌靶向治疗的靶点包括VEGFR、FGFR、PDGFR、RET 和KIT 等。信号转导与转录激活因子3 (STAT3)在多种恶性肿瘤中表达上调，并且STAT3 抑制剂已被证实具有抑制甲状腺癌细胞生长的能力，使STAT3成为一个潜在的甲状腺癌治疗靶点。本文综述了STAT3 和JAK/STAT 信号通路与肿瘤发生发展的关系，同时详细讨论了STAT3 在甲状腺癌中的功能，旨在为治疗甲状腺癌提供理论依据。

通讯作者：刘　枫 , Email:573174022@qq.com

Research progress of STAT3 in thyroid cancer

WU Sha-Sha¹ , LIU Feng^2,*

¹Laboratory of Human Diseases and Immunotherapy, West China Hospital, Sichuan University, Chengdu 610041, China ²Department of Thyroid surgery, West China Hospital, Sichuan University, Chengdu 610041, C

Abstract:

Thyroid cancer is a common endocrine malignancy with an increasing incidence worldwide. Most patients with thyroid cancers can get effective treatment, but the prognosis is somewhat worse for thyroid cancers which are difficult to remove surgically and for which iodine-131 treatment is not effective. Targets for targeted therapy of thyroid cancer include VEGFR, FGFR, PDGFR, RET, and KIT. The expression of signal transducer and activator of transcription 3 (STAT3) is increased in a variety of malignancies, and STAT3 inhibitors have been shown to inhibit tumor growth, making STAT3 a potential target for treating thyroid tumors. Therefore, the relationship between STAT3, JAK/STAT signaling pathway and cancer is summarized, and the role of STAT3 in thyroid cancer is also discussed, aiming to provide theoretical basis for the treatment of thyroid cancer.

Communication Author：LIU Feng , Email:573174022@qq.com